相关实验视频

Updated: Jun 11, 2025

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8⁺ T Cells During LN Metastasis

Published on: January 26, 2024

一个悖论性的瘤抗原在肝脏中的特定反应

Rajiv Trehan¹, Xiao Bin Zhu¹, Patrick Huang¹

¹Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

bioRxiv : the preprint server for biology

|October 7, 2024

概括

肝脏瘤含有大量但已经耗尽的CD8+ T细胞. 肝外瘤促进中间细胞群,抑制抗瘤免疫力,促进肝转移并降低免疫疗法的有效性.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
细胞生物学细胞生物学

背景情况:

功能性瘤特异性CD8+ T细胞对于抗瘤免疫力和免疫治疗成功至关重要.
与其他部位相比,肝转移表现出更多的CD8+ T细胞,但这些细胞往往表现出枯竭的表型.

研究的目的:

研究肝脏瘤中CD8+ T细胞的表型和功能.
阐明肝外瘤促进肝转移并损害抗瘤免疫力的机制.

主要方法:

鼠类瘤模型和来自患者的单细胞RNA测序 (scRNA-seq) 数据分析.
高维多原子分析集成蛋白质原子 CODEX 和 scRNA-seq.
功能性CD8+T细胞枯竭实验和Spp1淘汰赛小鼠模型.

主要成果:

透到肝脏瘤的CD8+ T细胞丰富而又枯竭,无法局部控制瘤生长,但对远程瘤有效.
SPP1+巨细胞与肝脏的益纤维细胞区域中的CD8+T细胞相互作用,导致T细胞耗尽.
缺少Spp1可以缓解T细胞的枯竭,并减少肝脏瘤的生长.
肝外信号诱导肝脏中的中间细胞 (IC) 群体,其特征是特定的表面标记物,这预测了肝脏转移.

结论:

肝外瘤通过诱导抑制CD8+T细胞功能的IC群体,创造了一个转移性肝脏微环境.
这种机制有助于肝转移,并可能限制免疫检查点抑制剂治疗肝癌的有效性.

更多相关视频

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.